dc.creatorPinto Paz, Mirian Elizabeth
dc.creatorCotrina Concha, Jose Manuel
dc.creatorBenites Zapata, Vicente A.
dc.date.accessioned2023-03-23T22:00:22Z
dc.date.accessioned2023-05-30T21:17:04Z
dc.date.available2023-03-23T22:00:22Z
dc.date.available2023-05-30T21:17:04Z
dc.date.created2023-03-23T22:00:22Z
dc.date.issued2021-01
dc.identifierCancer Treatment and Research Communications. 2021;29.
dc.identifier2468-2942
dc.identifierhttps://hdl.handle.net/20.500.12959/3509
dc.identifierhttps://doi.org/10.1016/j.ctarc.2021.100464
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/6450456
dc.description.abstractIntroduction: Cutaneous malignant melanoma (CMM) incidence has risen rapidly in the last 50 years. Poor progression and high mortality characterize CMM, making a thorough understanding of progression and associated factors essential for optimizing care. Aims: We assessed the association between the Neutrophil-to-Lymphocyte Ratio (NLR) and mortality in adults with CMM from an entirely mixed-race Hispanic population during 12 consecutive years of extensive follow-up. Material & Methods: We performed a retrospective cohort study in a tertiary hospital in Peru. NLR was categorized with a cutoff value higher or equal than 3. We collected demographic variables, laboratory results and treatments at baseline of follow-up. Cox regression analysis was performed, and we calculated crude and adjusted hazard ratios (HR) and their 95% confidence interval (95%CI). Results: The analysis was from 615 CMM cases, and there were 378 deaths. Most melanomas (63.6%) were acral lentiginous. The crude analysis showed that high NLR is a risk factor for mortality, HR = 2.52; 95%CI (2.03–3.14). High NRL ratio remains statistically significant after adjusting for confounding variables, aHR = 1.61; 95%CI (1.16–2.24). Other risk factors for mortality were clinical stages III and IV, older than 60 years, females and greater Breslow thickness. Conclusions: We concluded that high NRL ratio is a risk factor for mortality and should be monitored in every patient who is diagnosed with malignant melanoma during their first blood count. It should then be carried out in follow-up controls for patients of clinical stage III and IV only, or in patients who present a relapse.
dc.languageeng
dc.publisherElsevier
dc.relationhttps://www.sciencedirect.com/science/article/pii/S246829422100160X
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCutaneous malignant melanoma
dc.subjectNeutrophil-lymphocyte ratio
dc.subjectPrognosis
dc.subjectProgression
dc.subjectMelanoma maligno cutáneo
dc.subjectRelación neutrófilos-linfocitos
dc.titleMortality in cutaneous malignant melanoma and its association with Neutrophil-to-Lymphocyte ratio
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución